Recombinant ACT35 (Pogalizumab Biosimilar) anticorps

N° du produit ABIN7597916

Cet anticorps anti-ACT35 (Pogalizumab Biosimilar) Chimeric Humanized (ABIN7597916) détecte spécifiquement ACT35 (Pogalizumab Biosimilar). L’anticorps est réactif avec des échantillons de Humain.

Aperçu rapide pour Recombinant ACT35 (Pogalizumab Biosimilar) anticorps (ABIN7597916)

Antigène: ACT35 (Pogalizumab Biosimilar)

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Humanized

Clonalité: Chimeric

Classe de qualité: Research Grade

Détail du produit anti-ACT35 (Pogalizumab Biosimilar) anticorps

Expression System: Mammalian cells

Fonction: Research Grade Pogalizumab Biosimilar Antibody

Specificité: ACT35 antigen, TXGP1L, TAX transcriptionally-activated glycoprotein 1 receptor, Tumor necrosis factor receptor superfamily member 4, TNFRSF4, OX40L receptor, CD134

Purification: Protein A or G purified from cell culture supernatant.

Pureté: >95 % by SDS-PAGE.

Isotype: IgG1 kappa

Information d'application

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1.66 mg/mL

Buffer: 0.01M PBS, pH 7.4.

Stock: 4 °C,-20 °C,-80 °C

Stockage commentaire: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.

Date de péremption: 12 months

Détails sur ACT35 (Pogalizumab Biosimilar)

Antigène: ACT35 (Pogalizumab Biosimilar)

Autre désignation: Pogalizumab Biosimilar

Classe de substances: Biosimilar

Sujet: ACT35 antigen, TXGP1L, TAX transcriptionally-activated glycoprotein 1 receptor, Tumor necrosis factor receptor superfamily member 4, TNFRSF4, OX40L receptor, CD134

UniProt: P43489

Numéro CAS: 1638935-72-4